These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 8756381)

  • 1. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
    Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
    Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
    Lawlor PG; Turner KS; Hanson J; Bruera ED
    Cancer; 1998 Mar; 82(6):1167-73. PubMed ID: 9506365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
    Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
    J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.
    Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ
    J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent subcutaneous methadone administration in the management of cancer pain.
    Centeno C; Vara F
    J Pain Palliat Care Pharmacother; 2005; 19(2):7-12. PubMed ID: 16061456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study.
    Lawlor P; Turner K; Hanson J; Bruera E
    Pain; 1997 Aug; 72(1-2):79-85. PubMed ID: 9272790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Zimmermann C; Seccareccia D; Booth CM; Cottrell W
    J Pain Palliat Care Pharmacother; 2005; 19(2):25-31. PubMed ID: 16061458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous opioid dosing and outcomes in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Am J Emerg Med; 2010 Nov; 28(9):1041-1050.e6. PubMed ID: 20825766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine and alternative opioids in cancer pain: the EAPC recommendations.
    Hanks GW; Conno F; Cherny N; Hanna M; Kalso E; McQuay HJ; Mercadante S; Meynadier J; Poulain P; Ripamonti C; Radbruch L; Casas JR; Sawe J; Twycross RG; Ventafridda V;
    Br J Cancer; 2001 Mar; 84(5):587-93. PubMed ID: 11237376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences.
    Ripamonti C; De Conno F; Groff L; Belzile M; Pereira J; Hanson J; Bruera E
    Ann Oncol; 1998 Jan; 9(1):79-83. PubMed ID: 9541687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
    J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.